Melanotan II
| Names | |
|---|---|
| Pronunciation | /mɛˈlænoʊtæn/ ⓘ |
| Systematic IUPAC name
L-Lysinamide, N-acetyl-L-norleucyl-L-alpha-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic (2-7)-peptide | |
| Other names
List of other names
| |
| Identifiers | |
3D model (JSmol) |
|
| ChEMBL | |
| ChemSpider | |
| MeSH | melanotan-II |
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C50H69N15O9 | |
| Molar mass | 1024.180 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references | |
Melanotan II is a synthetic analogue of the peptide hormone α-melanocyte-stimulating hormone (α-MSH) that stimulates melanogenesis to facilitate tanning. It may also increase sexual arousal.
Melanotan II was originally developed as a tanning agent based on an earlier drug called afamelanotide (previously "Melanotan I") which is now approved by the FDA for the treatment of a particular rare genetic form of sun sensitivity. Melanotan II was later investigated as a potential treatment for sexual dysfunction, but development was abandoned in 2000 in order to pursue development of bremelanotide, a chemically similar drug later approved by the FDA for treatment of sexual dysfunction in women. Unlicensed Melanotan II is found on the internet, although health agencies advise against its use due to legality, case reports suggesting significant safety risks, and potential impurities.
Melanotan-II may cause reversible darkening of moles and freckles. It is unclear if Melanotan II can increase (or reduce) the risk of developing melanoma, because reports of melanomas associated with its use have coincided with heavy UV exposure and sun bed use. A 2013 scientific review found there was no conclusive evidence it causes melanoma, and a 2021 review concluded "the increased risk of melanoma in Melanotan users, who use it for tanning and exhibit sun-seeking behaviour, can probably be explained by more UV exposure".
Side effects may include facial flushing, nausea and erection in males.